Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial

Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial

Summary: Background: More effective vaccine candidates against variants of concern as a booster dose are needed in people primed with two-dose inactivated COVID-19 vaccines. Methods: This randomised, double-blinded, investigator-initiated phase 2 trial aims to evaluate immunogenicity, durability, a...

Full description

Bibliographic Details
Main Authors: Yuemiao Zhang, Xupu Ma, Guanghong Yan, Ying Wu, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Feng-Wei Liu, Mu-Xian Dai, Mei Yang, Chunmei Li, Xuanjing Yu, Liang Zhang, Zhongfang Wang, Tai-Cheng Zhou, Dingyun You, Jia Wei, Zijie Zhang
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:EClinicalMedicine
Subjects:
COVID-19 mRNA vaccine
Immunogenicity
Safety
Durability
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022004102

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022004102

Similar Items